Aligos Therapeutics, Inc.

Aligos Therapeutics reported a net loss of $24.5 million for the six months ended June 30, 2026, a significant decline from a net income of $27.2 million in the same period last year. The company disclosed substantial doubt about its ability to continue as a going concern, with current cash expected to fund operations only into the fourth quarter of 2026. Despite generating $27.8 million in licensing revenue, increased research and development expenses contributed to the overall loss and a higher cash burn from operations.

Aligos Therapeutics reported a significantly reduced net loss of $1.5 million for the second quarter of 2026, compared to $15.9 million in the prior year, driven by $27.778 million in licensing revenue. The company also announced substantial pipeline progress, including Breakthrough Therapy Designation in China for pevifoscorvir sodium and the completion of enrollment for its Phase 2 B-SUPREME study. Additionally, its partner Amoytop received IND approval in China for ALG-170675, triggering a $3 million milestone payment, further strengthening Aligos' financial position through non-dilutive capital.

Aligos Therapeutics, Inc. announced that it will report its second quarter 2026 financial results on Thursday, August 6, 2026. The results will be released before the U.S. financial markets open.

Aligos Therapeutics, Inc. announced the completion of enrollment for both HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in its global Phase 2 B-SUPREME study of pevifoscorvir sodium. This drug is being developed for the treatment of chronic hepatitis B virus (HBV) infection. The study enrolled 131 HBeAg+ and 114 HBeAg- participants, with topline safety and efficacy data anticipated in late third quarter of 2027.

Aligos Therapeutics announced that its drug candidate, pevifoscorvir sodium, received Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA), making it eligible for priority review. This follows the company receiving a $25 million upfront payment from Xiamen Amoytop Biotech Co., Ltd. as part of an exclusive license deal for pevifoscorvir sodium in Greater China. Aligos is also eligible for up to $420 million in clinical, regulatory, and sales milestones, along with tiered royalties on net sales.

Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders on June 25, 2026, where several proposals were approved. Key among these was an amendment to the 2020 Employee Stock Purchase Plan (ESPP), which reserves an additional 500,000 shares for issuance and eliminates the plan's "evergreen" provision for automatic share increases. Stockholders also re-elected two Class III directors, ratified the appointment of Ernst & Young LLP as independent auditors, and approved executive compensation on an advisory basis. The company will now hold advisory votes on executive compensation annually.

Aligos Therapeutics announced positive data from ten presentations at the European Association for the Study of the Liver (EASL) Congress 2026. Long-term follow-up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir. Notably, 40% of HBeAg+ participants treated with pevifoscorvir sodium achieved HBsAg reductions that could qualify them for functional cure therapy. Additionally, preclinical data showed additive to synergistic effects when pevifoscorvir sodium was combined with the antisense oligonucleotide ALG-170675.

Aligos Therapeutics announced that ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026. These presentations will detail progress on several of the company's drug candidates, including pevifoscorvir sodium and ALG-170675 for chronic hepatitis B (HBV), and ALG-055009 for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company will also present preclinical data on hepatitis delta virus (HDV) infections and a PD-1/PD-L1 inhibitor for HBV and liver cancer. The congress is scheduled from May 27-30, 2026, in Barcelona, Spain.

Aligos Therapeutics reported a net loss of $23.04 million for Q1 2026, a significant decline from a net income of $43.09 million in Q1 2025. The company's cash, cash equivalents, and short-term investments totaled $54.9 million as of March 31, 2026, which is expected to fund operations only into Q4 2026, raising substantial doubt about its ability to continue as a going concern. Revenue from customers increased to $2.83 million from $0.31 million year-over-year.

Aligos Therapeutics reported its first quarter 2026 financial results and significant business progress. The company received FDA Fast Track Designation for pevifoscorvir sodium for chronic HBV infection and entered an exclusive licensing deal with Amoytop for Greater China, including a $25 million upfront payment. The Phase 2 B-SUPREME study for pevifoscorvir sodium will continue after a positive interim analysis, with the DSMB recommending increased participant enrollment. For Q1 2026, Aligos reported a net loss of $23.0 million, with cash, cash equivalents, and investments totaling $54.9 million, expected to fund operations into Q4 2026.